Credit Suisse stated that CMS (00867.HK) -0.080 (-0.556%) Short selling $1.31M; Ratio 1.993% increased approximately 18% share capital in Tibet Pharma (600211.SH) at a cash consideration of RMB 785 million.
Credit Suisse lifted the target price of CMS from $12.83 to $15. However, since the stock is already trading at a premium to R&D-oriented pharma companies and the potential of the two new drugs was largely reflected in the share price, the rating of CMS was downgraded from Outperform to Neutral.
Credit Suisse lifted the target price of CMS from $12.83 to $15. However, since the stock is already trading at a premium to R&D-oriented pharma companies and the potential of the two new drugs was largely reflected in the share price, the rating of CMS was downgraded from Outperform to Neutral.
Comments
Post a Comment